MossRehab will soon begin the exclusive U.S. clinical trial for a new assistive technology called the ReWalk. The ReWalk is a motorized exoskeleton suit that enables patients with lower limb disabilities, including complete paralysis, to independently engage in ambulatory activities, such as standing, walking and in some cases climbing stairs.The ReWalk consists of a lightweight wearable brace support suit, motorized joints, rechargeable batteries, an array of sensors and a computer-based patient control system.Worn around the legs, chest and back, it fits closely to the body on top of everyday clothing. Patient stability during ambulation is provided by concurrent use of crutches.

The study, to be conducted under the direction of Alberto Esquenazi, MD, will be a single-center, open, noncomparative, non-randomized study of the safety and performance of the ReWalk.The overall objectives and endpoints of this clinical trial are to establish the safety and performance of the ReWalk suit and demonstrate initial efficacy and user satisfaction. A preliminary trial has been conducted in Israel to demonstrate safety. Availability of the device for clinical use is dependent upon FDA approval.

The ReWalk was developed by Argo Medical Technologies, a medical device company located in Haifa, Israel. For more information, contact Nancy Dawes at ndawes@einstein.edu.or visit www.MossRehab.org.